Insulet Corporation Class Action Reminder – Robbins LLP Encourages PODD Investors to Contact the Firm for Information About Their Rights

SAN DIEGO, July 21, 2026 (ZM NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and internationally.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that Insulet Corporation misled investors regarding the viability of its products. According to the complaint, during the class period, defendants failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Plaintiff alleges that on March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring” (the “March 2026 MDC”). On this news, Insulet’s stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026. Then, on May 26, 2026, Insulet disclosed the “initat[ion]” of another “voluntary Medical Device Correction” (the “May 2026 MDC”), this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, Insulet’s stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Insulet Corporation. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by August 31, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.

“Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness,” said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Insulet Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Amir Sohail